News
Galapagos’ filgotinib leads to rapid symptom improvement for ulcerative colitis patients
A post-hoc analysis from a Phase III clinical programme evaluating Galapagos’ filgotinib showed significant symptom improvements for patients with ulcerative colitis (UC).